Product image of Irbesartan/Hydrochlorothiazid - 1 A Pharma (Hydrochlorothiazide, Irbesartan) supplied by GNH India

Irbesartan/Hydrochlorothiazid - 1 A Pharma

Active Ingredient:
Hydrochlorothiazide, Irbesartan
Origin:
EU

Irbesartan/Hydrochlorothiazid - 1 A Pharma (Hydrochlorothiazide, Irbesartan)

Irbesartan, the active ingredient in Irbesartan/Hydrochlorothiazide - 1 A Pharma, is an Angiotensin II receptor blocker presented as an oral tablet for systemic use. It is combined with hydrochlorothiazide, a thiazide diuretic, to treat hypertension in adult patients.

GNH India supplies Irbesartan/Hydrochlorothiazide - 1 A Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Manufacturer / TM Owner

1 A Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Irbesartan/Hydrochlorothiazide is indicated for hypertension, acting on the renin‑angiotensin system and promoting diuresis.

  • Hypertension: reduces systolic and diastolic blood pressure, helping prevent stroke and heart attack.
  • Isolated systolic hypertension: provides effective control in elderly patients.
  • Hypertensive renal protection: assists in slowing progression of kidney disease in patients with elevated blood pressure.

How It Works

  • Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone‑mediated sodium retention. Hydrochlorothiazide inhibits the Na⁺/Cl⁻ cotransporter in the distal convoluted tubule, increasing urinary excretion of sodium and water and lowering plasma volume. The combined actions produce additive blood‑pressure‑lowering effects by addressing both vascular tone and fluid overload.

Side Effects

The combination may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Dizziness: light‑headedness, especially after initial dosing.
  • Headache: mild to moderate intensity.
  • Increased urination: due to the diuretic component.
  • Electrolyte imbalance: mild reductions in potassium or sodium levels.

Serious or Rare Side Effects

  • Severe hypotension: marked drop in blood pressure that can cause fainting.
  • Hyperkalemia: elevated potassium levels that may be dangerous.
  • Acute kidney injury: sudden decline in renal function.
  • Allergic reactions: rash, angioedema, or anaphylaxis.

Precautions & Warnings

Before prescribing Irbesartan/Hydrochlorothiazide, clinicians should consider several safety aspects.

  • Renal impairment: monitor kidney function and adjust therapy as needed.
  • Electrolyte disturbances: check serum potassium and sodium regularly.
  • Volume depletion: avoid in patients prone to dehydration or on high‑dose diuretics.
  • Pregnancy: contraindicated in the second and third trimesters; risk to fetus.
  • Concomitant drugs: review for interactions with potassium‑sparing agents or NSAIDs.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Avoid Interactions

Irbesartan/Hydrochlorothiazide can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

  • ACE inhibitors or aliskiren: risk of additive renal dysfunction and hyperkalemia.
  • Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.
  • Lithium: increased lithium levels, risk of toxicity.

Moderate Interactions (Monitor Closely)

  • NSAIDs: may reduce antihypertensive effect and impair renal function.
  • Cyclosporine or tacrolimus: can increase serum creatinine.
  • Antidiabetic agents: diuretic may affect glucose control.
  • Beta‑blockers: may enhance hypotensive effect.

Frequently Asked Questions

Irbesartan/Hydrochlorothiazide is an oral antihypertensive medication used to lower high blood pressure in adult patients. The combination targets both vascular tone through the angiotensin II pathway and fluid volume via diuresis, providing a comprehensive approach to blood‑pressure control.

Irbesartan blocks angiotensin II type 1 (AT1) receptors, preventing the hormone from causing blood‑vessel constriction and aldosterone‑driven sodium retention. This results in relaxed vessels and reduced blood‑volume pressure, contributing to lower systemic blood pressure.

The prescribed dose is determined by the treating physician based on the patient’s clinical condition, blood‑pressure response, and renal function. Healthcare providers select the appropriate strength and dosing schedule to achieve optimal control while minimizing adverse effects.

Use during pregnancy, especially in the second and third trimesters, is generally contraindicated because of potential fetal harm. Limited data are available for breastfeeding; the medication should be used only if the potential benefit justifies the possible risk to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other ARB‑thiazide combinations such as Losartan/HCTZ, Irbesartan offers a similar potency in AT1 receptor blockade but may have a slightly different side‑effect profile, particularly regarding potassium balance. Choice often depends on individual patient tolerance, physician preference, and formulary availability.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

The medication is taken orally, usually with a full glass of water. It can be taken with or without food, but patients should follow the prescribing clinician’s instructions regarding timing and whether to maintain consistent daily dosing.

Serious risks include severe hypotension, hyperkalemia (high potassium levels), acute kidney injury, and rare allergic reactions such as angioedema. Patients should be monitored for signs of these conditions, especially after initiating therapy or adjusting the dose.

The combination should be avoided in patients with known hypersensitivity to either component, severe renal impairment, significant hyperkalemia, or in pregnant women during the second and third trimesters. Clinicians should also exercise caution in individuals with a history of angioedema.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Hydrochlorothiazide, Irbesartan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT